https://www.selleckchem.com/products/sr59230a.html
4 % vs 2.4 %, p=0.025). Rate of cardiac death was actually low and consistent between the 2 groups (1.7 % vs 0.9 %, p=0.10. At 2-year, the rate of ST was 0.9 % in DM patients versus 0.5 % in non-DM, p=0.213. At 2-year, the Abluminus DES+ technology that merges the features of a sirolimus coated balloon with those of a bioresorbable polymer drug eluting stent appears to be safe and effective. This safety/efficacy profile was consistent in patients with or without DM. At 2-year, the Abluminus DES+ technology that merges the features of
Respect!
Kommentar
Delen
